Our Mission:
Scientific Solutions for Modern Hygiene
ViroWipe was developed to address the growing threat of antibiotic resistance and hospital-acquired infections through non-antibiotic infection control.
From Lab Concept to Global Distribution
2015
Development began through a collaboration between Helperby Therapeutics and the ViroWipe technical team.
2020
Proven effectiveness against all enveloped viruses, including SARS-CoV-2.
2021
Worldwide patent granted.
2022
Commercial launch with UK distributor Dee Set Logistics.
Production Partner
Thomas Swan, UK-based fine chemical blender.
Halal Certified
July 2021, Brenntag Bradford.
Our Team
Professor Sir Anthony Milnes Coates, BSc, FRCP, MD, FRCPath
Helperby Founder and Chief Scientific Officer
Professor Sir Anthony Milnes Coates, BSc, FRCP, MD, FRCPath
Helperby Founder and Chief Scientific Officer
Linda (Ms) Ball
Supracycling Global Chief Executive Officer (CEO)
Paul Pelham
Viroklenz Technical Director
Linda (Ms) Ball
Supracycling Global Chief Executive Officer (CEO)
Paul Pelham
Viroklenz Technical Director
Active Ingredients:
-
Chlorhexidine Digluconate
-
Didecyldimethyl Ammonium Chloride
-
Dimethyldecylamine Oxide
-
Non-Ionic Surfactant Blend
-
Alcohol Ethoxylates (C12–C15)
Log reductions across EN and ISO standards:
-
EN 1276: 5 Log (30s)
-
EN 16615: 5 Log (1 min)
-
ISO 15883: 8 Log (Bio-Film)
Effective against:
-
E. coli, P. aeruginosa, S. aureus, Enterococcus hirae
-
Yeasts, Moulds, Coliforms, Aspergillus
-
Vaccinia virus and all enveloped viruses including SARS-CoV-2
Target Applications:
- Medical devices
- food processing
- wound care (human and equine) institutional cleaning
- air duct sanitation
Our Locations
Head Office – UK
66 Lincoln’s Inn Fields, London WC2A 3LH
USA Office
15 Constitution Drive, Bedford, New Hampshire 03110
EU Office – Ireland
6th Floor, Grand Canal Square, Dublin 2
Production Site
ViroWipe Infection Control Ltd
Unit 4B, Buckshaw Link, Ordnance Road, Chorley, Lancashire PR7 7EL